Target countries : 

LiquiSoutheast Asia, South America, CIS

Highlights：

1. The indication of this product is targeted for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Ulcerative Colitis, Plaque Psoriasis.

2. This drug is registered as biosimilar in China.

3. Comparative study between ours and Humira on the aspect of quality part, preclinical and clinical part were made to prove similar safety and clinical efficacy with Humira.

Dosage form: 

Liquid for injection 

Specification: 

40mg/0.8ml, Syringe form

Indication: 

Used to treat many inflammatory conditions in adults, such as rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

Administration: 

Subcutaneously injection

Shelf life: 

24 months

Specific Requirements:

Deal in the related industry;
Familiar with local regulation for drug entry;
Familiar with local sales channel and market;
Active and confident in promoting the product.